Dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from Middle-East
Neurology Asia · 2021
DOI: 10.54029/2021jfx ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology Asia, 2021. Verfasst von Helia Hemasian und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Variable intravenous recombinant tissue-plasminogen activator (rt-PA) dosages are used for ischemic stroke. We aimed to report our experience from administering different rt-PA doses in a tertiary referral center in Middle-East.
Method
Medical documents of ischemic stroke patients who received rt-PA were retrospectively reviewed and analyzed. Patients were grouped into three categories based on the received total amount of rt-PA and their body weight: 0.6 mg/kg (low-dose), 0.75 mg/kg (intermediate-dose), and 0.9 mg/kg (high-dose). During the hospitalization period, patients were under full surveillance for rt-PA complications. The validated format of the National Institutes of Health stroke scale (NIHSS) and the modified Rankin scale (mRS) were used at the baseline, at the time of being discharged, and after 3 months. Chi-square, ANOVA, and ANCOVA were used for statistical analysis.
Results
602 patients were evaluated and grouped as follow: 187 (31.06%) in 0.6 mg/kg group (61% male) with mean age of 68±15 years, 217 (36.04%) in 0.75 mg/kg group (59% male) with mean age of 67±13 years, and 198 (32.89%) in 0.9 mg/kg group (50% male) with mean age of 69±17 years. There was no significant difference between the three groups regarding their demographics, comorbidities, and the distribution of stroke risk factors. No significant difference was seen between the three groups regarding in-hospital death and intracranial hemorrhage (p=0.07 and 0.09, respectively). In terms of NIHSS, no significant difference was observed between the three groups at the time of admission, discharge, and follow-up (p=0.98, 0.85, and 0.47, respectively). At the time of discharge, the mRS of 0.6 mg/kg group was significantly higher than the other two groups (p=0.04), which decreased in the 3-month follow-up and did not make significant differences (p=0.38).
Conclusions
According to the in-hospital mortality, intracranial hemorrhage, mRS, and NIHSS scores, we recommend 0.75 mg/kg as our safe, beneficial, and cost-effective dosage.
Zitieren
APA
Hemasian, H., Sheikhbahaei, E., Shahzamani, A., Khorvash, F., Saadatnia, M., & Rastinmaram, Z. (2021). Dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from Middle-East. Neurology Asia. https://doi.org/10.54029/2021jfx
Vancouver
Hemasian H, Sheikhbahaei E, Shahzamani A, Khorvash F, Saadatnia M, Rastinmaram Z. Dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from Middle-East. Neurology Asia. 2021. doi:10.54029/2021jfx
BibTeX
@article{Hemasian2021,
author = {Hemasian, Helia and Sheikhbahaei, Erfan and Shahzamani, Arvin and Khorvash, Faribourz and Saadatnia, Mohammad and Rastinmaram, Zahra},
title = {Dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from Middle-East},
journal = {Neurology Asia},
year = {2021},
doi = {10.54029/2021jfx}
}
EUVIMED